PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 17 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
MeOH stem bark extract (100 mg/kg po) produced approximately 47% inhibition of carrageenin-induced paw oedema and over 30% reduction in pain sensitivity [PMID:11535356].
Methanolic extracts demonstrated potent anti-cancer activity in vitro with IC(50) = 0.2-1.3 μg/ml [PMID:23565862]. Specific compounds erythrofordins D and E showed cytotoxicity in the low micromolar range (mean GI50 of 2.45 and 0.71 μM respectively) [PMID:30553734].
Extracts inhibited the growth of Trichophyton rubrum and T. mentagrophytes [PMID:8531930].
Evidence summary
PubMed sources
- 1.PMID: 31453295 (2019) — Spectroscopic data of new cassane diterpenoids from the root bark of Erythrophleum suaveolens. · Data in brief
- 2.PMID: 11535356 (2001) — Anti-inflammatory and analgesic properties of the stem bark extracts of Erythrophleum suaveolens (Caesalpiniaceae), Guillemin & Perrottet. · Journal of ethnopharmacology
- 3.PMID: 32763366 (2020) — Five new cassane diterpenes from the seeds and bark of Erythrophleum suaveolens. · Fitoterapia
- 4.PMID: 31389269 (2021) — Three novel non-nitrogenous cassane diterpenoids from Erythrophleum suaveolens (Guill. et Perr.) Brenan (Fabaceae). · Natural product research
- 5.PMID: 30553734 (2019) — Erythrofordins D and E, two new cassaine-type diterpenes from Erythrophleum suaveolens.